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Abstract
Background: High salt intake is linked to hypertension whereas a restriction of dietary salt lowers blood pressure (BP).
Substituting potassium and/or magnesium salts for sodium chloride (NaCl) may enhance the feasibility of salt restriction
and lower blood pressure beyond the sodium reduction alone. The aim of this study was to determine the feasibility
and effect on blood pressure of replacing NaCl (Regular salt) with a novel mineral salt [50% sodium chloride and rich in
potassium chloride (25%), magnesium ammonium potassium chloride, hydrate (25%)] (Smart Salt).
Methods: A randomized, double-blind, placebo-controlled study was conducted with an intervention period of
8-weeks in subjects (n = 45) with systolic (S)BP 130-159 mmHg and/or diastolic (D)BP 85-99 mmHg. During the
intervention period, subjects consumed processed foods salted with either NaCl or Smart Salt. The primary endpoint
was the change in SBP. Secondary endpoints were changes in DBP, daily urine excretion of sodium (24-h dU-Na),
potassium (dU-K) and magnesium (dU-Mg).
Results: 24-h dU-Na decreased significantly in the Smart Salt group (-29.8 mmol; p = 0.012) and remained
unchanged in the control group: resulting in a 3.3 g difference in NaCl intake between the groups. Replacement of
NaCl with Smart Salt resulted in a significant reduction in SBP over 8 weeks (-7.5 mmHg; p = 0.016). SBP increased
(+3.8 mmHg, p = 0.072) slightly in the Regular salt group. The difference in the change of SBP between study
groups was significant (p < 0.002).
Conclusions: The substitution of Smart Salt for Regular salt in subjects with high normal or mildly elevated BP
resulted in a significant reduction in their daily sodium intake as well as a reduction in SBP.
Trial Registration: ISRCTN: ISRCTN01739816
Keywords: blood pressure, hypertension, sodium reduction, mineral salt, low-sodium, high-potassium and high-
magnesium salt
Background
Hypertension is a major risk factor for cardiovascular
diseases (CVD) as well as for renal diseases [1]. Redu-
cing salt intake lowers blood pressure and consequently
lowers the risk of cardiovascular disease. The observed
decline in the prevalence of hypertension has levelled off
[2,3]. Therefore, there is an evident need for public
health measures aiming at more effective lifestyle modi-
fications connected to high BP including the reduction
of sodium intake [4-7].
Meta-analyses show that a daily sodium reduction of
at least 53 mmol (3.1 g/day as sodium chloride (NaCl))
c a nl e a dt oar e d u c t i o no f4 - 5m m H gi ns y s t o l i cB P
(SBP) and 2-3 mmHg in diastolic BP (DBP) in hyperten-
sive subjects [8-15].
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a low-sodium diet may enhance the antihypertensive
effect of a low-sodium diet, and thus be useful in treat-
ing hypertension [16-18]. Potassium has a natriuretic
effect, promoting the excretion of sodium salts in the
urine [17]. Intake of magnesium may also support BP
lowering by reducing vascular resistance [19].
Earlier studies have demonstrated the antihypertensive
effect of replacing normal salt with low-sodium, potas-
sium and magnesium containing mineral salt [20-26].
Accomplishing the sodium restriction has been challen-
ging and target levels are not achieved in everyday life. It
has been estimated that cutting down salt concentrations
in processed foods could be the most feasible way to
reduce salt intake at the population level [7,27,28].
Only preliminary data is available on mineral salt con-
taining magnesium over 2% of total weight. The goal of
this study was to test the feasibility and effect of a new
mineral salt (Smart Salt) on blood pressure, which is low
in sodium and high in potassium and magnesium. The
hypothesis of the study was that the replacement of Smart
Salt for a regular salt covering at least 50% of dietary
sodium sources in a diet would lead to a 3 to 5 g reduction
in sodium intake and consequently a lower SBP.
Methods
Subjects
Subjects were recruited via announcements in the local
newspapers and from the volunteer register of Oy Food-
files Ltd in the Kuopio area, Eastern Finland. A written
consent form was obtained from each subject. Subjects
were eligible if they were between 25-75 years old, with
their SBP in the range of 130-159 mmHg and/or DBP in
the range of 85-99 mmHg, BMI between 23 and 40 kg/m
2
and a stable body weight. Subjects were excluded if they
were taking antihypertensive drugs, non-steroidal anti-
inflammatory agents, cyclosporine or tacrolimus. They
were also excluded if they had secondary hypertension,
diabetes (type 1 or 2), a history of active heart disease or
cancer, abnormal electrolytes, proteinuria, abnormal liver,
kidney or thyroid function. Subjects were also excluded if
they were currently on a low-salt diet (six or less points in
the salt intake test by the Finnish Heart Association, Hel-
sinki). Subjects with alcohol abuse (> 14 units per week)
or drug abuse were excluded. Pregnant and lactating
mothers were also excluded.
Study Design
This was a randomized, double-blind, placebo-controlled,
parallel study (Figure 1). The study consisted of six study
visits, beginning with 2 visits during the 3-5 week run-in
period on a habitual diet. At the third visit (week 0), the
subjects were randomized into one of the two study
groups: test (Smart Salt group) or control (Regular salt
group) for 8 weeks. The study was conducted according
to the guidelines laid down in the Declaration of
Helsinki. The Ethics Committee of the Hospital District
of Northern Savo approved the study protocol.
Study products and diets
The test product was Smart Salt
® SMS50 supplied by
Smart Salt
® Inc (California USA). Smart Salt
® contained
50% sodium chloride (NaCl), 25% potassium chloride
(KCl) and 25% magnesal; magnesium ammonium potas-
sium chloride, hydrate [Mg4K(NH4)3Cl12·24H2O]. The
control was a regular salt (sodium chloride, NaCl) (Akzo
Nobel Salt, Netherlands).
During the treatment period, the main food sources of
salt were either salted as normal or with Smart Salt
®,
depending on the study group. Test foods were indust-
rially processed main dishes (casseroles, soups, pastas,
pizza and minced meat dishes), bread (70% rye bread and
30% multigrain), frankfurters sausage/cold cuts and Edam
cheese. Salt used for cooking and baking as well as table
salt was either regular salt or Smart Salt
®,d e p e n d e n to n
group.
The daily amount of the test foods in the study diet was
based on national dietary data in Finland, namely the Fin-
Diet 2007 study. In the test group, the NaCl reduction was
designed to be 3.1 to 5.6 grams (1.2 to 2.2 grams Na
+)
depending on the energy intake and habitual diet of the
study subject. The goal was to replace approximately 60%
of the regular sources of sodium with Smart Salt products
in the intervention group. The daily sodium intake in the
Regular Salt group was designed to stay at the same level
as typical for that individual. The amounts of Smart Salt
and Regular Salt in recipes of test foods were the same.
The analyzed concentration of sodium (expressed as
NaCl) in the test foods varied between 0.38-1.41% in
S m a r tS a l tf o o d sa n d0 . 6 4 - 2 . 0 3 %i nR e g u l a rs a l tf o o d s
depending on the food matrix.
All study subjects were told by a nutritionist to refrain
from salt-rich products (such as salty snacks, soy sauce,
olives, salt-rich cheeses, stock cubes, salty and smoked fish
etc.). The use of products containing bioactive peptides
(like Evolus
®), salts other than the test salts, licorice
(Radix glycyrrhizae), ammonium chloride products and
any food supplements that might affect BP were also pro-
hibited. Study subjects could freely consume liquid dairy
products, vegetables, fruits and berries in addition to the
study foods.
Blood pressure and heart rate measurements
BP and heart rate were measured using an automatic
sphygmomanometer (Omron M4-I, fully automatic BP
monitor, Omron Matsusaka Co, Ltd, Japan) following 10
minutes rest in a sitting position. BP was measured three
times with intervals of at least two minutes, between the
hours of 7:00 am and 12:00 noon. The mean of the last
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sured using the non-dominant arm with the exception of
the first study visit during which BP was measured using
both arms. If the BP in the two arms differed in SBP or
DBP by more than 10 mmHg, the arm with the higher
reading was used for all subsequent measurements. Volun-
teers were not told the results of their BP measurements
during the study and the study nurse was unaware of the
treatment allocations.
Weight and height measurements
Body weight was measured using a calibrated digital scale
(Scale Seca 704, Medical scales and measuring systems
Seca GmbH & Co, Germany). Height was measured with
a Seca telescoping measuring rod type 221 (Vogel &
Halke GmbH & Co, Germany) to the nearest crossed half
a centimeter at the first study visit (-4 wk). Body mass
index (BMI) was calculated with the equation: weight
(kg)/height (m)
2.
24-hour urine collection
The subjects completed 24 hour urine collections twice
during the study; before the intervention period (-1 day)
and once at end of the intervention period (+8 wk). Urine
collections were required to account for a minimum of
20 hours and a maximum of 28 hours, with the amount
lost being ≤ 10% of total urine. Urine samples were ana-
lyzed for sodium, potassium, magnesium and creatinine at
the ISLAB laboratories, Kuopio. Urinary creatinine was
analyzed using an enzymatic method. Urinary potassium
and sodium were measured using an ion-specific electrode
(ISE). Magnesium was measured using atomic absorption
spectrometry. The completeness of urine excretion was
checked in the present study by calculating the sodium
excretion in relation to 24-hour creatinine excretion.
Blood Samples
Blood samples were taken after a 10 to 12 hour overnight
fasting period and after BP had been measured. Blood
samples were analyzed using standardized methods of
hematology and clinical chemistry at the ISLAB labora-
tories, Kuopio. Plasma sodium and potassium were ana-
lyzed by ion-specific electrode and plasma magnesium was
analyzed using atomic absorption spectrometry.
Study Diaries
The compliance of the test protocol was assured using
individual diaries in which the use of test products was
recorded. The subjects also recorded in their daily diary
their weight, any possible adverse effects, changes in life-
style and medications during the study.
Data management and statistical analysis
Data management and analyses were performed using
SPSS (version 17.0, SPSS Inc, Chicago, USA). The results
are presented as means and standard deviations. The nor-
mal distribution of variables was checked using the
Shapiro-Wilk test. The equality of variances among the
study groups was tested using the Levene test. The equal-
ity of variance-covariance matrices across cells was tested
using the Box’s M test. The general linear model (GLM)
for repeated measures was used to test between-groups
and with-in group differences using repeated continuous
variables. In the event of a significant time/group interac-
tion, independent sample t-tests were conducted using the
Bonferroni correction in among-group analyses and com-
parisons within groups were conducted using paired sam-
ple t-tests. For the continuous variables, which were not
normally distributed even after logarithmic transforma-
tion, the Mann-Whitney test (among groups) and
Wilcoxon test or Friedman test (with-in group) were
Run-in period Treatment period
Regular Salt group
S m a r tS a l tg r o u p
͘ ͘ ͘͘ ͘ ͘ ͘͘
-4 week -2 week 0 week 3 week 6 week 8 week
Blood samples
͘ BP and heart rate measurement
24-h urine collection
Figure 1 Study Design. This randomized, double-blind, placebo-controlled, parallel study was comprised of a run-in period and a treatment
period.
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values less than 0.05 were regarded as statistically
significant.
Results
Subjects
Telephone screening was performed on 72 volunteer male
and 96 female volunteers. Of those screened by telephone
fifty (50) eligible subjects (24 men and 26 women) were
randomized into the study. Forty five (45) subjects (22 in
the Smart Salt group and 23 in the Regular salt group)
completed the study and were included in the data analy-
sis (90% completion rate). At baseline, there were no sig-
nificant differences between the study groups in mean BP,
BMI or any of the routine laboratory measurements
(Table 1). The most typical energy level in the Smart
Salt group was 2200 kcal and in the Regular Salt group
2000 kcal respectively.
Consumption of test products
The mean daily consumption of test products was 95%
in the Smart Salt group and 88% in the Regular salt
group, according to the subject’s diaries. During the
intervention period, the Smart Salt group used an aver-
age of 1.9 (± 2.2) grams of table salt per day and the
Regular salt group used an average of 1.3 (± 1.0) grams
per day (NS).
Dietary sodium chloride intake
The sodium chloride (NaCl) intake calculated from dU-Na
and product diaries are
presented in Table 2. At the end of the 8 week inter-
vention, mean daily NaCl intake calculated from dU-Na,
was significantly less in the Smart Salt group compared
to that of the Regular salt group (-3.3 g; p < 0.002). In the
Smart Salt group, daily NaCl intake, decreased by 2.0
grams compared to baseline (p = 0.012) while the change
from baseline in the Regular salt group was insignificant.
T h ed i f f e r e n c ei na b s o l u t ec h a n g eo fN a C li n t a k e
between study groups was of borderline statistical signifi-
cance (p = 0.05) whereas the percentage change between
study groups was statistically s i g n i f i c a n t( n e td i f f e r e n c e
-21.6%; p = 0.033) (Table 2).
The mean daily NaCl intake as calculated using the pro-
duct diaries was 3.2 grams less in the Smart Salt group
compared to the Regular salt group during the interven-
tion period (p < 0.001). Daily NaCl intake decreased on
average by 3.5 grams in the Smart Salt group and by 1.7 g
in the Regular salt group in comparison to baseline dU-Na
data.
Blood pressure
The changes in SBP and DBP from baseline were signifi-
cantly different between the study groups (p < 0.002 and
p = 0.014, respectively). There was a decrease in both
Table 1 Characteristics of the study subjects
Smart Salt
®
(n = 22)
Regular salt
(n = 23)
Female/Male (n) 13/9 9/14
Age (years) 57 (12) 54 (11)
Pre-trial blood pressure (mmHg)
1
Systolic 141 (8) 138 (9)
Diastolic 87 (6) 88 (7)
Pre-trial body weight (kg) 77 (12) 85 (17)
Body weight (kg) (Visit 3) 77 (12) 85 (16)
Body weight (kg) (Visit 6) 77 (13) 84 (16)
Pre-trial body mass index (kg/m
2) 28 (3) 28 (3)
Body mass index (kg/m
2) (Visit 3) 28 (3) 28 (3)
Body mass index (kg/m
2) (Visit 6) 28 (3) 28 (3)
Smokers (n) 33
Alcohol users (n) 18 21
Subjects having regular
2 exercise (n) 19 19
Pre-trial consumption of salt (points)
3 11.7 (2.5) 11.9 (1.4)
Subjects using vitamin/mineral supplements before intervention (n) 13 10
Subjects using vitamin/mineral supplements during intervention (n) 87
Subjects using other food supplements (n) 78
1 mean of two measurements (Visit 1, -4 weeks and Visit 2, -2 weeks).
2 exercising at least 2-3 times/week for 30 minutes or more.
3 according to the salt intake test (Finnish Heart Association, Helsinki).
P-values < 0.05 are considered as statistically significant.
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intervention period (Figure 2). The mean SBP decreased
b y7 . 5±1 0 . 1m m H ga n dt h eD B Pd e c r e a s e db y2 . 7±
4.5 mmHg. In contrast, there was a slight increase in
S B Pa n dD B Pi nt h eR e g u l a rs a l tg r o u p( + 3 . 8a n d+ 1 . 5
mmHg, respectively).
There was a significant difference in mean SBP
between the study groups at week 3 (p = 0.028) and a
nearly significant difference (p = 0.076) at the end of
intervention (Table 3). The mean values of SBP and DBP
in the Smart Salt group vs Regular Salt group are shown
in Table 3. Also the mean DBP tended to be lower for
the Smart Salt group compared to the Regular salt group,
but the differences were not statistically significant
(Table 3).
24-hour urinary sodium, potassium, magnesium and
creatinine
In the Smart Salt group there was a decrease in dU-Na
during 8 weeks compared to baseline (-29.8 mmol; p =
0.012), whereas there was no significant change over time
in the Regular salt group. At 8 week mean dU-Na in
S m a r tS a l tg r o u pw a ss i g n i f i cantly less than that of the
Regular Salt group (-50 mmol, p < 0.002) (Table 4). The
difference in absolute change of dU-Na between study
groups was of borderline statistical significance (net dif-
ference 28.8 mmol; p = 0.050) (Table 4). However, in per-
centage terms dU-Na decreased significantly (p = 0.033)
more in Smart Salt group (-18.5 ± 28.8%) compared to a
slight increase in Regular Salt group (+3.0 ± 34.7%).
The between group difference remained statistically sig-
nificant when dU-Na values were adjusted with dU-Crea
values (p = 0.004).
Following 8 weeks of treatment, dU-K in the Smart Salt
group increased by 16.0 mmol (a non significant change)
and decreased in the Regular salt group (-15.7 mmol; p =
0.034) (Table 4). There was a significant difference (p =
0.002) in the mean of dU-K between the study groups at
end of intervention (Table 4). The change in dU-K (0 vs 8
wk) differed also in absolute (Table 4 p < 0.001) and per-
centage terms (+30.9 ± 46.1 vs -14.2, ± 36.4; p = 0.001)
between the study groups.
Table 2 Daily salt intake (as NaCl) during intervention
Smart Salt
®
(n = 22)
Mean (SD)
Regular salt
(n = 23)
Mean (SD)
p-value
Daily NaCl intake during intervention (calculated from product diaries) (grams) 5.3 (1.6) 8.5 (2.0) p < 0.001
1
Daily NaCl intake calculated from dU-Na (grams)
Visit 3 (-1 day) 8.8 (3.2) 10.2 (2.9) NS
2
Visit 6 (+8 weeks) 6.8 (3.3) 10.1 (3.1) p < 0.002
2
p-value
3 p = 0.012 NS
Changes in daily NaCl intake during intervention calculated from dU-Na
grams -2.0 (3.6) -0.1 (2.8) NS (p = 0.050)
4
% -18.5 (28.8) 3.1 (34.7) p = 0.033
1
Changes in daily NaCl intake during intervention calculated from baseline dU-Na and
NaCl intake calculated from diaries
grams -3.5 (2.9) -1.7 (3.7) NS
1
% -35.1 (21.6) -7.8 (40.0) p = 0.007
1
1 Indicates the significance of difference between the groups analyzed with Mann-Whitney test.
2 Indicates the significance of difference between the groups analyzed with Mann-Whitney test with Bonferroni corrections.
3 Indicates the significance of difference within the group analyzed with Wilcoxon test with Bonferroni corrections.
4 Indicates the significance of difference between the groups analyzed with independent samples t-test.
P-values < 0.05 are considered as statistically significant.
NS = non-significant
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Figure 2 The change in systolic (SBP) and diastolic blood
pressure (DBP) are illustrated as means ± standard deviations.
P-values indicate the statistical significance for difference between
the groups.
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values of dU-Mg between nor within the study groups. In
Smart Salt group, dU-Mg tended to increase (+0.60
mmol) following 8 weeks intervention and in the Regular
salt group, dU-Mg tended to decrease (-0.21 mmol)
(Table 4). However, these absolute changes in dU-Mg
(Table 4, p = 0.028) and percentage changes in dU-Mg
(+20.2 ± 46.4 in Smart Salt group vs -4.4 ± 27.6% in Reg-
ular Salt group; p = 0.021) differed between the study
groups significantly.
Plasma sodium, magnesium and creatinine concentra-
tions remained stable during intervention and there were
no significant differences between the study groups.
Within the Regular salt group, plasma potassium con-
centrations decreased over the 8-week intervention
(0.2 mmol/l; p = 0.024).
Adverse events
During the intervention period, there were 7 reports of
respiratory symptoms (Smart Salt group n = 5/Regular salt
group n = 2), 17 reports of abdominal/intestinal symptoms
(12/5) and 3 reports of cardiovascular symptoms (1/2).
None of the adverse events were deemed to be related to
the test salts.
Discussion
Substitution of Smart Salt for Regular Salt in processed
foods was a feasible measure that enabled the volunteers
to achieve the recommended salt intake level of 5-6 grams
per day. Previous studies have reported that the daily NaCl
reduction should be at least 3.1 g to achieve a reduction of
4 to 5 mmHg in SBP and 2 to 3 mmHg in DBP in hyper-
tensive subjects [13]. In this study, a reduction of only
2.0 grams (measured by dU-Na) to 3.2 grams (measured
by product diaries) resulted in a marked decrease of mean
SBP (-7.5 mmHg) in the Smart Salt group in contrast to a
slight increase of mean SBP (+3.8 mmHg) in the control
group.
At baseline, daily sodium urinary excretion and dietary
NaCl intake were at typical (or slightly lower) levels con-
sumed in western populations [29,30] The food diaries
indicated that those in the Smart Salt group had their daily
intake of sodium (as NaCl) reduced by 3.5 g compared to
the Regular salt group. Also the difference in urinary
sodium excretion between the groups at the end of inter-
vention indicated a 3.3 g difference in mean sodium intake.
The consumption of Smart Salt mineral salt produced
a stronger effect on BP than could be expected based on
observed sodium excretion and previous pure sodium
restriction studies [8-15]. The results reported in this
paper indirectly suggest that potassium and magnesium
could potentiate the effect of sodium restriction on
reducing BP. This effect is in line with earlier clinical
trials with mineral salts [16,20-26].
An increase of urinary potassium excretion of 63 mmol/
24 hour has been associated with a decrease in supine SBP
Table 3 Systolic and diastolic blood pressure during the intervention period
Smart Salt
®
(n = 22)
Regular salt (n = 23) p-value p-value
Systolic blood pressure (mmHg) p < 0.001
1
Visit 3 (0 week) 140 (13) 134 (9) NS
3
Visit 4 (+3 weeks) 133 (8)
a 140 (9) p = 0.028
3
Visit 5 (+6 weeks) 132 (10)
b 139 (10) NS
3
Visit 6 (+8 weeks) 132 (7)
c 138 (9) NS (p = 0.076)
3
p-value
1 (p < 0.001)
p-value
2 p = 0.016 NS (p = 0.072)
Diastolic blood pressure (mmHg) p = 0.007
1
Visit 3 (0 week) 89 (8) 88 (7) NS
3
Visit 4 (+3 weeks) 86 (6) 90 (6) NS
3
Visit 5 (+6 weeks) 86 (6) 91 (8) NS
3
Visit 6 (+8 weeks) 86 (7) 90 (7) NS
3
p-value
1 (p = 0.007)
p-value
2 NS (p = 0.094) NS
1 Indicates the significance of the time*group interaction analyzed with the GLM for repeated measures.
2 Indicates the significance of difference within the groups analyzed with the GLM for repeated measures with Bonferroni corrections.
3 Indicates the significance of difference between the groups analyzed with the independent samples t-test with Bonferroni corrections.
Letters indicate significance of within-group difference compared to baseline (0 wk) analyzed with paired t-test with Bonferroni corrections.
a p = 0.081
b p = 0.024
c p = 0.006
P-values < 0.05 are considered as statistically significant.
NS = non-significant
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Whelton et al. [17], supplementation with 2 g potassium
decreases blood pressure an average of 2 to 3 mmHg. In
our study, the net change in potassium excretion was
about 30 mmol/24 hours, predicting a 3 mmHg reduction
in SBP. The sodium to potassium ratio seems to be more
important in potentiating the effect on BP than individual
mineral modifications [32]. It has been postulated that the
effect of potassium supplementation is reduced by half if
simultaneous daily sodium intake is under 3.2 g (8 g NaCl)
and can be increased by double if sodium intake is over
3.8 g (9.5 g NaCl). Interestingly our result indirectly indi-
cates that potassium substitution could be useful even at
the recommended 5-6 g NaCl intake.
The high efficacy of mineral salts used in lowering BP
might also be partly explained by the increase in magne-
sium intake. Magnesium supplementation has little direct
effect on BP, especially in hypertensive subjects [32-37].
However magnesium may have an effect on BP through
interactions with sodium and potassium [20,38]. Magne-
sium concentration was exceptionally high in the tested
mineral salt (2.3% of total weight).
It should noted that the novel mineral enrichment
used in the processed foods was likely to enhance the
good compliance to sodium restriction throughout the
study in the Smart Salt group. The taste profile of test
products was good and products could not be differen-
tiated from each other. It can be assumed that similar
Table 4 Total urinary sodium (du-Na), potassium (dU-K), magnesium (dU-Mg) and creatinine (dU-Crea) excretion in
24-h period before (-1 day) and during (+8 wk) the intervention
Smart Salt
(n = 22)
Regular salt
(n = 23)
p-value p-value
dU- Na (mmol)
Visit 3 (-1 day) 130 (47) 151 (44) NS
1
Visit 6 (+8 weeks) 100 (49) 150 (46) p < 0.002
1
p-value p = 0.012
2 NS
2
Change: 0 wk vs +8 wk -29.8 (53.3) -0.9 (42.0) NS (p = 0.050)
3
dU-K (mmol) p = 0.003
4
Visit 3 (-1 day) 79 (31) 82 (22) NS
5
Visit 6 (+8 weeks) 95 (32) 66 (22) p = 0.002
5
p-value
3 (p = 0.003)
p-value NS
6 p = 0.034
6
Change: 0 wk vs +8 wk 16.0 (37.4) -15.7 (29.0) p < 0.001
7
dU-Mg (mmol) NS
8 NS
4
Visit 3 (-1 day) 4.54 (1.61) 4.67 (1.24)
Visit 6 (+8 weeks) 5.14 (1.97) 4.46 (1.67)
p-value
9 (NS)
Change: 0 wk vs +8 wk 0.60 (1.82) -0.21 (1.31) p = 0.028
7
dU-Crea (mmol)
Visit 3 (-1 day) 12 (4) 14 (4) NS
1
Visit 6 (+8 weeks) 11 (4) 12 (4) NS
1
p-value NS
2 p = 0.030
2
dU-Na/dUCrea
Visit 3 (-1 day) 11.5 (4.1) 11.9 (3.8) NS
1
Visit 6 (+8 weeks) 11.7 (12.7) 12.7 (4.0) p = 0.004
1
p-value NS
2 NS
2
Mean (SD).
1 Indicates the significance of difference between the groups analyzed with the Mann-Whitney test with Bonferroni corrections.
2 Indicates the significance of difference within the group analyzed with the Wilcoxon test with Bonferroni corrections.
3 Indicates the significance of difference between the groups analyzed with the independent samples t-test.
4 Indicates the significance of the time*group interaction analyzed with the GLM for repeated measures.
5 Indicates the significance of difference between the groups analyzed with the independent samples t-test with Bonferroni corrections.
6 Indicates the significance of difference within the group analyzed with the paired samples t-test with Bonferroni corrections.
7 Indicates the significance of difference between the groups analyzed with the Mann-Whitney test.
8 Indicates the significance of difference between the groups analyzed with the GLM for repeated measures.
9 Indicates the significance of difference within the groups analyzed with the GLM for repeated measures.
P-values < 0.05 are considered as significant.
NS = non-significant
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ple salt restriction advice only. The self-reported com-
pliance with the use of test foods and salts was good
and biochemical data support this view.
Importantly lifestyle, weight and possible medications
remained stable during the intervention. Thus the results
could be principally ascribed to the intervention with
Smart Salt low-sodium, high-potassium, high-magnesium
mineral salt. Since the sample size in this proof-of concept
study was relatively small, results will need to be repeated
and verified with a larger sample size.
Salt substitution in processed foods and table salt may
have a large impact on cardiovascular health at population
level. Recently published analysis demonstrated that redu-
cing salt by 3 g per day is projected to reduce the annual
number of new cases of CHD by 60 000 to 120 000 in
USA alone [7].
In conclusion, the use of Smart Salt in processed
foods helped subjects to bring their sodium intake in
line with the recommended levels of 2.3 g/day (5.75 g as
NaCl) [5]. Additionally, this study indicates that repla-
cing regular salt with a mineral salt low in sodium, high
in potassium and high in magnesium may be a feasible
way to potentiate antihypertensive effect in subjects with
mild hypertension.
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